中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2288-2292

Value of liver biopsy in the diagnosis and clinical trial of non-alcoholic fatty liver disease

DOI: 10.12449/JCH241124

  • Department of Gastroenterology，Shanghai General Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200080，China

Research funding:

General Project of National Natural Science Foundation of China (82170620)

More Information
  • Corresponding author: LU Lungen， lungenlu1965@163.com （ORCID： 0000-0002-1533-4068）
  • Received Date: 2024-03-05
  • Accepted Date: 2024-04-19
  • Published Date: 2024-11-25
    Abstract
  • Non-alcoholic fatty liver disease （NAFLD） constitutes a series of histological lesions characterized by varying degrees of hepatocyte damage， fat accumulation， inflammation， and fibrosis. Currently， liver biopsy is considered the “gold standard” for evaluating the degree of hepatic steatosis， inflammation， and fibrosis， and it also serves as the cornerstone for accurate grading of NAFLD. This article reviews the value and application of liver biopsy in the clinical diagnosis， staging， and clinical trials of NAFLD.

     

    • FullText(HTML)
  • loading
    • References(34)
  • [1]
    ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67( 1): 123- 133. DOI: 10.1002/hep.29466.
    [2]
    DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377( 21): 2063- 2072. DOI: 10.1056/NEJMra1503519.
    [3]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
    [4]
    ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158( 7): 1999- 2014. e 1. DOI: 10.1053/j.gastro.2019.11.312.
    [5]
    WANG YK, WEI SY, LIU C, et al. A new definition of fatty liver disease: from nonalcoholic fatty liver disease to metabolic associated fatty liver disease[J]. Chin J Dig Surg, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.

    王永康, 魏诗雨, 刘昌, 等. 脂肪性肝病新定义:从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病[J]. 中华消化外科杂志, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.
    [6]
    SAIMAN Y, DUARTE-ROJO A, RINELLA ME. Fatty liver disease: Diagnosis and stratification[J]. Annu Rev Med, 2022, 73: 529- 544. DOI: 10.1146/annurev-med-042220-020407.
    [7]
    NASR P, IGNATOVA S, KECHAGIAS S, et al. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies[J]. Hepatol Commun, 2018, 2( 2): 199- 210. DOI: 10.1002/hep4.1134.
    [8]
    YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 1): 11- 20. DOI: 10.1038/nrgastro.2017.109.
    [9]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [10]
    CHITTURI S, WONG VW, CHAN WK, et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups[J]. J Gastroenterol Hepatol, 2018, 33( 1): 86- 98. DOI: 10.1111/jgh.13856.
    [11]
    ZHANG XY, LIU Y, WANG WL, et al. Diagnosis and evaluation of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.

    张馨元, 刘宇, 王文玲, 等. 非酒精性脂肪性肝病的诊断与评估[J]. 临床肝胆病杂志, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.
    [12]
    YU L, LU LG. Progress in the diagnosis and treatment of non-alcoholic steatohepatitis[J]. Int J Dig Dis, 2023, 43( 4): 217- 220. DOI: 10.3969/j.issn.1673-534X.2023.04.002.

    俞楼, 陆伦根. 非酒精性脂肪性肝炎的诊治进展[J]. 国际消化病杂志, 2023, 43( 4): 217- 220. DOI: 10.3969/j.issn.1673-534X.2023.04.002.
    [13]
    GOODMAN ZD. Role of liver biopsy in clinical trials and clinical management of nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2023, 27( 2): 353- 362. DOI: 10.1016/j.cld.2023.01.017.
    [14]
    KLEINER DE, BRUNT EM, Van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41( 6): 1313- 1321. DOI: 10.1002/hep.20701.
    [15]
    KLEINER DE, BRUNT EM, WILSON LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2019, 2( 10): e1912565. DOI: 10.1001/jamanetworkopen.2019.12565.
    [16]
    SHEKA AC, ADEYI O, THOMPSON J, et al. Nonalcoholic steatohepatitis: A review[J]. JAMA, 2020, 323( 12): 1175- 1183. DOI: 10.1001/jama.2020.2298.
    [17]
    CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67( 1): 328- 357. DOI: 10.1002/hep.29367.
    [18]
    BRUNT EM, KLEINER DE, CARPENTER DH, et al. NAFLD: Reporting histologic findings in clinical practice[J]. Hepatology, 2021, 73( 5): 2028- 2038. DOI: 10.1002/hep.31599.
    [19]
    BEDOSSA P, FLIP PATHOLOGY CONSORTIUM. Utility and appropriateness of the fatty liver inhibition of progression(FLIP) algorithm and steatosis, activity, and fibrosis(SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60( 2): 565- 575. DOI: 10.1002/hep.27173.
    [20]
    NASCIMBENI F, BEDOSSA P, FEDCHUK L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2020, 72( 5): 828- 838. DOI: 10.1016/j.jhep.2019.12.008.
    [21]
    ANGULO P, HUI JM, MARCHESINI G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology, 2007, 45( 4): 846- 854. DOI: 10.1002/hep.21496.
    [22]
    SHAH AG, LYDECKER A, MURRAY K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7( 10): 1104- 1112. DOI: 10.1016/j.cgh.2009.05.033.
    [23]
    FURLAN A, TUBLIN ME, YU L, et al. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease[J]. AJR Am J Roentgenol, 2020, 214( 1): W20- W26. DOI: 10.2214/AJR.19.21267.
    [24]
    SONG Q. Elastogrphy piont quantification in diagnosis of nonalcoholic fatty liver disease[J]. Chin J Ultrasound Med, 2021, 37( 2): 157- 159.

    宋倩. 剪切波组织定量技术在非酒精性脂肪肝诊断中的意义[J]. 中国超声医学杂志, 2021, 37( 2): 157- 159.
    [25]
    ZHENG WW, YU H, ZHENG H. Application value of liver hardness measurement by two-dimensional ultrasonic shear wave elastography in nonalcoholic fatty liver disease[J]. J Clin Exp Med, 2024, 23( 7): 764- 767. DOI: 10.3969/j.issn.1671-4695.2024.07.024.

    郑伟伟, 俞慧, 郑慧. 二维超声剪切波弹性成像技术肝脏硬度测量在非酒精性脂肪性肝病疾病严重程度预测中的应用价值[J]. 临床和实验医学杂志, 2024, 23( 7): 764- 767. DOI: 10.3969/j.issn.1671-4695.2024.07.024.
    [26]
    PAPATHEODORIDI M, HIRIART JB, LUPSOR-PLATON M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease[J]. J Hepatol, 2021, 74( 5): 1109- 1116. DOI: 10.1016/j.jhep.2020.11.050.
    [27]
    PETTA S, WONG VW, CAMMÀ C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values[J]. Hepatology, 2017, 65( 4): 1145- 1155. DOI: 10.1002/hep.28843.
    [28]
    NIERHOFF J, CHÁVEZ ORTIZ AA, HERRMANN E, et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: A meta-analysis[J]. Eur Radiol, 2013, 23( 11): 3040- 3053. DOI: 10.1007/s00330-013-2927-6.
    [29]
    ZHAO GD, GUO SM, XIE Q, et al. Diagnostic accuracy of FibroScan-AST score in nonalcoholic steatohepatitis with significant activity and fibrosis[J]. J Clin Hepatol, 2022, 38( 6): 1288- 1292. DOI: 10.3969/j.issn.1001-5256.2022.06.014.

    赵钢德, 郭斯敏, 谢青, 等. Fibroscan-ast评分对具有显著活动性和纤维化的非酒精性脂肪性肝炎患者的诊断效能[J]. 临床肝胆病杂志, 2022, 38( 6): 1288- 1292. DOI: 10.3969/j.issn.1001-5256.2022.06.014.
    [30]
    ANANIA FA, DIMICK-SANTOS L, MEHTA R, et al. Nonalcoholic steatohepatitis: Current thinking from the division of hepatology and nutrition at the food and drug administration[J]. Hepatology, 2021, 73( 5): 2023- 2027. DOI: 10.1002/hep.31687.
    [31]
    NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT): A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385( 9972): 956- 965. DOI: 10.1016/S0140-6736(14)61933-4.
    [32]
    SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362( 18): 1675- 1685. DOI: 10.1056/NEJMoa0907929.
    [33]
    CHEUNG A, NEUSCHWANDER-TETRI BA, KLEINER DE, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: Recommendations from the liver forum[J]. Hepatology, 2019, 70( 5): 1841- 1855. DOI: 10.1002/hep.30672.
    [34]
    SANYAL AJ, BRUNT EM, KLEINER DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis[J]. Hepatology, 2011, 54( 1): 344- 353. DOI: 10.1002/hep.24376.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (103) PDF downloads(24) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return